BPG is committed to discovery and dissemination of knowledge
Articles in Press
10/20/2025 11:24:07 AM | Browse: 21 | Download: 0
Category |
Oncology |
Manuscript Type |
Prospective Study |
Article Title |
Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant
|
Manuscript Source |
Invited Manuscript |
All Author List |
Marina A Senchukova, Evgeniya Yu Zubareva, Natalia V Saidler and Lyubov V Krivolapova |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Russian Science Foundation |
23-25-00183 |
|
Corresponding Author |
Marina A Senchukova, Scientific and Clinical Center No. 3, Petrovsky National Research Centre of Surgery, Oktyabrsky Prospekt, 3, Moscow 108840, Troitsk, Russia. masenchukova@yandex.com |
Key Words |
Breast cancer; Chemoresistance; Programmed death-ligand 1; Programmed cell death protein 1-ligand 1; Сytoplasmic programmed cell death protein 1 ligand 1 |
Core Tip |
We immunohistochemically studied the expression of programmed cell death protein 1 Ligand 1 (PDCD1 LG1) in tumor cells (TCs) and immune cells (ICs) in patients with breast cancer (BC). We revealed that a lack of cytoplasmic PDCD1 LG1 (cPDCD1 LG1) expression in ≥ 20% of TCs is characteristic of more aggressive BC subtypes, namely, G3 tumors, estrogen receptor-negative status and human epidermal growth factor receptor-2 overexpression. In addition, we established that the combined assessment of the lack of cPDCD1 LG1 expression in TCs and the PDCD1 LG1 score in ICs is one of the most significant predictors associated with BC chemotherapy sensitivity. |
Citation |
Senchukova MA, Zubareva EY, Saidler NV, Krivolapova LV. Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant. World J Exp Med 2025; In press |
 |
Received |
|
2025-06-18 10:24 |
 |
Peer-Review Started |
|
2025-06-18 10:24 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-06-30 07:11 |
 |
Revised |
|
2025-07-13 20:03 |
 |
Second Decision |
|
2025-10-20 03:00 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-10-20 11:24 |
 |
Articles in Press |
|
2025-10-20 11:24 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
ISSN |
2220-315x (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345